Krishna Institute Of Medical Sciences Ltd announces an acquisition

Sarvottam Health Care’s latest cited financials are for FY2025-26 (FY26), but audited-statement status could not be confirmed from the cited disclosure. Turnover/revenue was Rs 84.83 Crores. EBITDA and debt were not reported in the cited information, so EBITDA margin and leverage cannot be reliably calculated. The same disclosure cites PAT of Rs 7.06 Crores and net worth of Rs 50.30 Crores. ^[1]

Remaining 49% stake

• Call option: A secondary transaction summary refers to a “call option agreement,” but it does not provide the option language, exercise period, pricing mechanism, or confirm that this is a term of the Share Purchase Agreement. The official filing confirms only that KIMS entered definitive agreements to acquire up to 51%; therefore, a call option over the remaining 49% could not be confirmed from the primary disclosure. ^{[2] [1]}
• Defined acquisition timeline: No timeline for acquiring the remaining 49% is established. The 31 October 2026 deadline relates to completion of the initial 51% acquisition, not the balance stake. ^[3]
• The separate O&M agreement has an initial five-year term with a possible five-year extension; that is an operating-contract term, not a stated timetable for buying the remaining shares. ^[4]

Conclusion: KIMS has a documented path to acquire 51%, but the available primary disclosure does not establish either a binding call option or a defined schedule for acquiring the remaining 49%.

At Rs79.50 crore for 51%, Sarvottam implies an equity valuation of approximately Rs155.88 crore. That equates to approximately Rs85.18 lakh per installed bed on a 100%-equity-value basis, or Rs43.44 lakh per bed based only on KIMS's cash outlay for the 51% stake. The transaction's EV/EBITDA multiple cannot be calculated from the reported data because Sarvottam's EBITDA and net debt were not provided.

Implied valuation

The 22.08x figure is an equity-value-to-PAT cross-check, not an EV/EBITDA multiple. It is broadly consistent with the approximately 22x FY26 profit multiple reported by Avior Advisory, although that commentary used the transaction's stated maximum consideration of about Rs80 crore ^[6]. The official regulatory announcement also described the consideration as up to Rs80 crore, whereas the later transaction report cited Rs79.50 crore; the calculations above use the Rs79.50 crore specified in the question ^{[2] [1]}.

Comparison with KIMS's acquisition benchmarks

A quantified comparison with KIMS's historical acquisition EV/EBITDA or cost-per-bed benchmarks could not be confirmed from the cited material. The available KIMS transaction commentary identifies other O&M-linked hospital investments, but does not provide a consistent historical series of purchase EVs, EBITDA, net debt and bed counts on a comparable basis ^{[7] [6]}.

Analytical read: the Sarvottam price looks like a 22x FY26 PAT control-equity valuation, with the more defensible operating benchmark being Rs85 lakh per bed on an implied 100% equity basis. It should not be labelled “22x EBITDA” or compared directly with KIMS's historical EV/EBITDA acquisition multiples until target EBITDA and deal-level debt/cash are available.

Verdict: Assuming the Rs 79.50 crore payment is funded from cash and no offsetting financing or operating cash generation is considered, it would materially reduce KIMS’s reported liquidity and raise net debt-to-equity from 1.42x to approximately 1.45x. However, the transaction cannot be confirmed as funded entirely through internal accruals; the disclosure confirms a cash payment and remittance, but does not identify the funding source.

Immediate balance-sheet impact

KIMS reported consolidated cash and equivalents of Rs 55.40 Crores as of Q4 FY26, carried forward as the latest Q1 FY27 figure ^[8]. Against this, the reported transaction consideration was up to Rs 79.50 crore ^[1], although the regulatory filing described the consideration as up to Rs 80.00 crore and confirmed that it had been remitted ^[2].

The cash outflow is therefore approximately 143.50% of the latest reported cash-and-equivalents balance, derived from Rs 79.50 crore and Rs 55.40 Crores. This is a meaningful liquidity event, but the negative cash result is a mechanical calculation rather than an assertion that KIMS’s actual post-payment cash balance was negative. The latest reported cash figure predates the acquisition payment and does not capture subsequent cash generation or financing flows.

Was it funded entirely through internal accruals?

Not confirmed. The regulatory disclosure establishes only that this was a cash consideration and that the consideration was remitted ^[2]. It does not state that the payment came exclusively from internal accruals.

KIMS’s broader stated funding framework was mixed: proceeds from its QIP were intended to support operations and growth, including acquisitions and expansion, alongside debt reduction; management also referred to using cash flows for future expansion after retiring some debt ^[7]. That framework is not consistent with an assumption that every acquisition is funded solely through internal accruals.

The clean conclusion is therefore:

• Liquidity: materially tighter on a standalone cash basis; the payment exceeded the latest reported cash balance.
• Leverage: mechanically increases net debt-to-equity to about 1.45x, assuming no offsetting cash generation or equity funding.
• Funding source: cash-funded transaction, but exclusive internal-accrual funding is not established. The precise mix between operating cash, QIP proceeds and other available funds remains unconfirmed.
• Caveat: the actual post-acquisition ratio could differ once the payment date balance sheet, target-company cash/debt and consolidation effects are reported.